| SMARCD1, also known as BAF60A, is a core subunit of the mammalian SWI/SNF (BAF) chromatin remodeling complexes, working alongside BRG1 or BRM ATPases and scaffold proteins such as BAF155 and BAF170. As a member of the SMARCD (BAF60) family, which includes A, B, and C isoforms, SMARCD1 acts as a crucial adaptor bridging the catalytic machinery of the complex to sequence-specific transcription factors, thereby facilitating ATP-dependent nucleosome remodeling essential for both gene activation and repression. SMARCD1 is characterized by four tandem SWI3-like domains that form a compact α-helical scaffold, with a conserved motif in the fourth domain enabling direct, hormone-dependent binding to the coactivator grooves of androgen and glucocorticoid receptors as well as to p53 transactivation domains, while its N-terminal region mediates interaction with BRG1. SMARCD1 is pivotal for dynamic chromatin reconfiguration; it recruits the BAF complex to promoters marked by H3K27me3 or bivalent chromatin, such as those of developmental regulators and Klf4, where it helps restrict pluripotency and promote lineage commitment in embryonic stem cells through redistribution of H3K27me3 and acquisition of H3K4me3 at transcription start sites. SMARCD1 also interfaces with the glucocorticoid receptor to enable hormone-responsive gene activation and partners with p53 to mediate stress responses, while influencing senescence-associated lipid metabolism via integration with the Rb pathway. SMARCD1 fine-tunes embryonic stem cell differentiation, regulates hormone-driven proliferation, and modulates cellular senescence by balancing lipid droplet accumulation and chromatin accessibility. SMARCD1 mutations disrupt BAF complex integrity in cancers such as rhabdoid tumors and ATRT, enhance Notch signaling in glioblastoma, and contribute to aging-related lipotoxicity, with loss of SMARCD1 mimicking the effects of broader SWI/SNF impairment on glucocorticoid receptor and p53 target gene regulation. |
